VEC.L Regulatory News (VEC)

Vectura Group plc

Interim Dividend Timetable

Chippenham, UK - 26 May 2021: Vectura Group plc (LSE: VEC) ("Vectura "), announced earlier this morning a recommended cash acquisition by Murano Bidco Limited, and in connection therewith, announced the withdrawal of the special dividend of 19 pence per Vectura ordinary share (the "Special Dividend"), the share consolidation and the dividend reinvestment plan previously announced on 21 April 2021, and the declaration of an interim cash dividend of 19 pence per Vectura ordinary share (the "Interim Dividend") in replacement of the previous Special Dividend. The schedule below sets out the key dates in respect of the Interim Dividend.

Expected Timetable of Principal Events

- Ends -

For more information, please contact:

Vectura Group plc

John Murphy - Company Secretary +44 (0)207 881 1206

David Ginivan - VP Corporate Communications +44 (0)7471 352 720

Olivia Manser - Director, Investor Relations +44 (0)7947 758 259

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Melissa Gardiner / David Daley

About Vectura

Vectura is a leading specialist inhalation CDMO that provides innovative inhaled drug delivery solutions that enable customers to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com